Daxor Corporation (NASDAQ:DXR) Short Interest Update

Daxor Corporation (NASDAQ:DXR) was the target of a large decrease in short interest during the month of July. As of July 31st, there was short interest totaling 348 shares, a decrease of 76.4% from the July 15th total of 1,472 shares. Based on an average daily volume of 1,908 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are short sold.

Daxor Stock Down 1.7%

Shares of NASDAQ DXR traded down $0.18 during midday trading on Friday, reaching $10.22. 530 shares of the stock traded hands, compared to its average volume of 1,721. Daxor has a one year low of $8.56 and a one year high of $14.76. The company’s 50 day moving average is $10.35 and its 200 day moving average is $10.74.

Hedge Funds Weigh In On Daxor

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. bought a new stake in shares of Daxor in the 2nd quarter worth about $86,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Daxor in the 4th quarter valued at approximately $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of Daxor during the 1st quarter valued at approximately $245,000. Crescent Grove Advisors LLC purchased a new stake in Daxor during the 1st quarter valued at $104,000. Finally, Aristides Capital LLC bought a new stake in Daxor in the first quarter worth $403,000. 1.34% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Daxor in a report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Daxor presently has an average rating of “Moderate Buy”.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA?100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA?100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.